The World Health Organisation. The World Health. Report 1997. Geneva.
2.
RossR.The pathogenesis of atherosclerosis: A perspective for the 1990's. Nature1993; 362: 801–9.
3.
MurrayCL, LopezAD.Alternative projections of mortality and disability by cause, 1990-2020: Global Burden of Diseases Study. Lancet1997; 349: 1498–1504.
4.
WoodD, DurringtonP, PoulterN, McInnesG, ReesA, WrayR.Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart1998; 80(suppl 2):S1–S29.
5.
WilsonPW, AgostinoRB, LevyD.Prediction of coronary heart disease using risk factor categories. Circulation1998; 97: 1837–47.
6.
CarlisleSS, NahataM.Chlamydia pneumoniae and coronary heart disease. Ann Pharmacother1999; 33: 615–22.
7.
FolsomAR.Antibiotics for prevention of myocardial infarction?Not yet! JAMA1999; 281: 461–2.
8.
OslerW.Diseases of the arteries. In OslerW, ed. Modern medicine: its practice and theory.Philadelphia: Lea and Febiger, 1908: pp 429–47.
9.
PatelP, MendallMA, CarringtionD.Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. Br Med J1995; 311: 711–4.
10.
MendallMA, GogginPM, MolineauxN, LevyJ.Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J1994; 71: 437–9.
11.
GrattenMT, Moreno-CabralCE, StamesVA.Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA1989; 261: 3561–6.
12.
LowryRW, AdamE, HuC, KleimanNS.What are the implications of cardiac infection with cytomegalovirus before heart transplantation?J Heart Lung Transplant1994; 13: 122–8.
13.
SaikkuP, LeinonenM, LinnanmakiE.Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki heart study. Ann Intern Med1992; 116: 273–8.
14.
SaikkuP.Chlamydia pneumoniae infection as a risk factor in acute myocardial infarction. Eur Heart J1993; 14(suppl): 62–5.
KuoCC, ShorA, CampbellLA, FukushiA, PattonDL, GraystonJT.Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis1993; 167: 841–9.
17.
WangSP, GraystonJT.Population prevalence of antibody to Chlamydia pneumoniae strain TWAR. In: BowieWR, StammWE, WardME, eds, Chlamydial infections.Cambridge, Cambridge University Press, 1990: pp 402–5.
18.
ThornDM, GraystonJT, SiscovickDS, WangSP, WeissNS, DalingJR.Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA1992; 268: 68–72.
19.
MuhlesteinJB.Chronic infection and coronary artery disease. Med Clin North Am2000; 84: 123–48.
20.
WiembickiWB, HagmeyerKO.Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus: chronic infections and coronary heart disease. Pharmacother2000; 20: 52–63.
21.
GraystonJT.Antibiotic treatment trials for secondary prevention of coronary artery disease events. Circulation1999; 99: 1538–9.
22.
KuoCC, GraystonJT, CampbellLA, GooYA, WisslerRW, BendittEP.Chalamydia Pneumoniae (TWAR) in coronary arteries of young adults (15-35 years old). Proc Natl Acad Sci U S A1995; 92: 6911–14.
23.
MaassM, BartelsQ, EngelPM, MarnatU, SieversHH.Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol1998; 31: 827–32.
24.
FongW, ChiuB, VidaE.Rabbit model for Chlamydia pneumoniae infection. J Clin Microbiol1997; 65: 4832–5.
25.
SchussheimAE, FusterV.Antibiotics for myocardial infarction? A possible role of infection in artherogenesis and acute coronary syndromes. Drugs1999; 57: 28391.
26.
LaitinenK, LauffiaA, PyhalaL.Chlamydia pneumoniae infection induces inflammatory changes in the aorta of rabbits. Infect Immun1997; 65: 4832–5.
27.
GuptaS, LeathamEW, CarringtonD.Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation1997; 96: 404–7.
28.
GurfinkelE, BozovichG, BeckE.Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. Eur Heart J1999; 20: 121–7.
29.
SinisaloJ, MattilaK, NieminenMS.The effect of prolonged doxycycline therapy on Chlamydia pneumoniae serological markers, coronary heart disease risk factors and forearm basal nitric oxide production. J Antimicrob Chemother1998; 41: 85–92.
30.
JacksonLA, StewartDK, WangS-P.Safety and effect on anti-Chlamydia pneumoniae antibody titres of a one-month course of daily azithromycin in adults with coronary artery disease. J Antimicrob Chemother1999; 44: 411–4.
31.
TorganoG, CosentiniR, MandelliC.Treatment of Helicobacter pylori and Chlamydia pneumoniae infections decreases fibrinogen plasma level in patients with ischemic heart disease. Circulation1999; 99: 1555–9.
32.
MeierCR, DerbyLE, JickSS, VasilakisC, JickH.Antibiotics and risk of subsequent first-time acute myocardial infraction. JAMA1999; 281: 427–31.
33.
MelissanoG, BlasiF, EspositoG.Chlamydia pneumoniae eradication from carotid plaques. Results of an open, randomised treatment study. Eur J Vasc Endovasc Surg1999; 18: 355–9.
34.
AndersonJL, MuffiesteinJB, CarlquistJ.Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. Circulation1999; 99: 1540–7.
35.
GraystonJT, KuoQ, WangS, AltmanJ.A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infection. N Engl J Med1986; 315: 161–8.
36.
HammschlagMR.Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae.Antimicrob Agents Chemother1994; 38: 1837–8.
37.
PedersenTR, KjekshusJ, BergK.Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Circulation1994; 344: 1383–9.
38.
SacksFM, KefferMA, MoyeLA.The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Eng J Med1996; 335: 1001–9.
39.
DunneM.WIZARD and the design of trials for secondary prevention of atherosclerosis with antibiotics. Am Heart J1999; 138: S542–3.
40.
LipGY, BeeversDG.Can we treat coronary artery disease with antibiotics?Lancet1997; 350: 378–9.
41.
GuptaS.Chlamydia pneumoniae, monocyte activation, and azithromycin in coronary heart disease. Am Heart J1999; 138: S539–41.
42.
GraystonJT, JacksonLA, KennedyWJ, KronmalRA.Secondary prevention trials for coronary artery disease with antibiotic treatment for Chlamydia pneumoniae: Design issues. Am Heart J1999; 138: S545-9.
